DLA Piper advised Haemonetics in USD $255 million acquisition of Canadian medical device maker ‎OpSens

On December 12, 2023, global medical technology company Haemonetics Corp. (NYSE: HAE), closed its previously-announced acquisition of all outstanding shares of Canadian medical device maker OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF) in an all-cash transaction valued at USD$255 million.

DLA Piper’s cross-border team advising Haemonetics was led by Adam Ghander in the US and Robert Fonn and Ted Maduri in Canada. “Our US and Canadian teams coordinated to provide a cross-border experience for Haemonetics and we are delighted that we could offer the Québec and public M&A capability needed for a deal of this type,” said Fonn and Maduri. 

The deal team representing Haemonetics also included Carly Meredith, Jamie Mandell, Michael Jamieson, Marc Philibert, Alexandre Lamoureaux, Francois Tremblay, Geoff Mowatt (IP), Elexa Clement, Marley Mintzberg, Kevin Wright (foreign investment), Nicole Nazareth, Alan Sarhan, Kevin Fritz (tax), Rownock Zamani, Annie-Claude Authier, David Spratley (IP), Alexis Bass, Nathalie Benoit, and Katrina Kotarba.

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 13 consecutive years, according to Mergermarket, and number one in M&A in combined global deal volume according to PitchBook.